Drug-eluting balloons in the treatment of de-novo coronary lesions: a meta-analysis of randomized-controlled trials

作者：Li, Ying; Wang, Cuancuan; Zuo, Guoxing; Wang, Kuan; Cao, Zhongnan; Du, Xinping^*

来源：Coronary Artery Disease, 2016, 27(6): 467-477.

DOI：10.1097/MCA.0000000000000372

• bare-metal stents
• coronary artery disease
• drug-coated balloon
• drug-eluting stents
• percutaneous coronary intervention

Aim The aim of this meta-analysis was to evaluate the efficacy of drug-eluting balloons (DEBs) plus bare-metal stents (BMS) for the treatment of de-novo coronary lesions.
Methods and results Eleven trials involving 1279 patients were included in this study. The main endpoints were as follows: late lumen loss (LLL), binary restenosis, stent thrombosis (ST), and major adverse cardiovascular events (MACEs). The definition of MACEs was a composite of death, myocardial infarction (MI), and target lesion revascularization (TLR). Compared with BMS alone, DEB plus BMS showed a lower risk for LLL (P=0.007) and MACEs (P=0.010). There were no significant differences in binary restenosis (P=0.212), ST (P=0.199), death (P=0.141), MI (P=0.439), and TLR (P=0.340). Compared with drug-eluting stents (DES), DEB plus BMS could increase the risk of LLL (P=0.002) and MACEs (P=0.026). The risks of binary restenosis (P=0.113), ST (P=0.832), death (P=0.115), MI (P=0.831), and TLR (P=0.111) were similar between DEB plus BMS and DES.
Conclusion DEB plus BMS was better than BMS alone in reducing LLL and MACEs, especially when dilatation was performed after stenting for de-novo coronary lesions, but it was inferior to DES. Therefore, the treatment strategy with DEB plus BMS should not be recommended for de-novo coronary lesions, except for patients who have contraindications for DES.

• 出版日期2016-9
• 单位天津市第五中心医院